iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today
announced it will showcase its Breast AI Suite of cancer detection,
density assessment and risk evaluation solutions at the world’s
largest breast imaging conference, the Society of Breast Imaging
(SBI) Symposium, taking place May 4-7 in National Harbor, MD.
Attendees are invited to visit the iCAD booth #507 to see the
Company’s Breast AI Suite in action and learn how leading
clinicians worldwide are overcoming imaging challenges, including
decreasing the incidence of interval cancers.
“While mammography screening has improved in recent decades and
the introduction of digital breast tomosynthesis (DBT) offers many
clinical advantages, it also creates enormous amounts of data.
Processing this volume of data can weigh heavily on radiologists
and imaging teams,” said Dana Brown, President and CEO of iCAD,
Inc. “iCAD’s Breast AI Suite offers a 360-degree solution of cancer
detection, density assessment, and risk evaluation technologies
that are uniquely positioned to address the top challenges
clinicians face today. Not only is our solution clinically proven
to improve accuracy and efficiency for radiologists reading
mammography, it offers critical information about a woman’s present
and future breast health, which can help clinicians find more
interval breast cancers at their earliest stage possible.”
Interval cancers, or those that are diagnosed in between
screening exams after a “normal” mammogram, tend to be larger and
more aggressive, diagnosed at a later stage and with worse
prognoses than those found on screening mammograms.1 In a study of
69,025 women, interval breast cancers accounted for one-fourth of
breast cancers in routinely screened women. These interval cancers
were six times more likely to be grade III and had 3.5 times
increased hazards of breast cancer death compared with
screen-detected cancers.1
Laura Dean, MD, breast radiologist, Cleveland Clinic, recently
discussed minimizing interval cancers with AI in a presentation at
the Siemens Healthineers Innovations for Healthcare Professionals
Education Symposium in New Orleans, LA.
“DBT has improved mammography screening considerably,
particularly in the U.S., where it is available at 82% of breast
imaging sites.2 However, DBT has introduced new challenges for
radiologists reading mammography, as it generates an exponential
amount of data to review, compared to 2D mammography. AI is
becoming ubiquitous in our daily lives, from smartphones to smart
homes, but it is particularly well-suited for reading DBT,” said
Dr. Dean. “Interval cancers tend to grow and possibly spread more
quickly, making them among the most dangerous to miss. AI helps us
to review every pixel of even the most complicated datasets more
closely, and with greater accuracy and efficiency, which helps us
detect more cancers earlier and hopefully decrease the incidence of
interval cancers.”
A growing body of clinical evidence confirms the unique value
iCAD’s Breast AI Suite offers to clinicians and patients alike.
According to a retrospective analysis of 37,367 women published in
the Journal of Medical Screening, ProFound® AI for 2D Mammography
may reduce interval breast cancer rates, as the technology found
93% of interval cancers—including eight out of nine cancers that
presented with minimal signs and six out of six that were false
negatives, or missed in the screening round.3 Additionally, a study
published in Science Translational Medicine suggests ProFound AI
Risk offered high accuracy in estimating future risk for both
screen detected and interval cancers, as well as invasive and
in-situ cancers, in both women with dense and non-dense
breasts.2
The flagship product in iCAD’s Breast AI Suite is ProFound AI,
which became the first technology of its kind to be FDA cleared in
2018. Built with the latest in deep-learning AI, ProFound AI for
Digital Breast Tomosynthesis is clinically proven to improve
radiologists’ sensitivity by 8%, reduce the rate of false positives
and unnecessary callbacks by 7%, and slash reading time by more
than half. iCAD’s Breast AI Suite also includes PowerLook Density
Assessment, which automates the process of breast density reporting
and empowers clinicians to further personalize breast cancer
screening recommendations for patients.
The latest addition to iCAD’s Breast AI Suite, ProFound AI Risk,
is the world’s first clinical decision support tool that provides
an accurate short-term breast cancer risk estimation that is truly
personalized for each woman, based only on her mammogram.4,5 This
first-in-kind solution uniquely combines age, breast density and
subtle mammographic features, offering superior performance and
accuracy in assessing both short- and long-term risk compared to
traditional, commonly-used breast cancer risk models.3,6
“Breast cancer continues to be one of the greatest threats to
women’s health worldwide, but iCAD’s Breast AI Suite arms
clinicians with more intelligence than ever to personalize
screening based on individual risk, which can help them detect
cancers at their earliest possible stages, when they may be more
easily treated,” said Ms. Brown. “Using our suite of tools together
provides clinicians with the latest defense in the fight against
breast cancer – not only does it empower them to perform at a
higher level, but it offers valuable information about patients’
individual risk of developing breast cancer that can help
clinicians tailor screening regimens. This translates to finding
more cancers and we look forward to sharing our powerful solutions
with the clinical community at the SBI Symposium this week.”
About iCAD, Inc.Headquartered in Nashua, NH,
iCAD® is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit
www.icadmed.com.
Forward-Looking
Statements
Certain statements contained in this News Release constitute
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements
about the expansion of access to the Company’s products,
improvement of performance, acceleration of adoption, expected
benefits of ProFound AI®, the benefits of the Company’s products,
and future prospects for the Company’s technology platforms and
products. Such forward-looking statements involve a number of known
and unknown risks, uncertainties and other factors which may cause
the actual results, performance, or achievements of the Company to
be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking
statements. Such factors include, but are not limited, to the
Company’s ability to achieve business and strategic objectives, the
willingness of patients to undergo mammography screening in light
of risks of potential exposure to Covid-19, whether mammography
screening will be treated as an essential procedure, whether
ProFound AI will improve reading efficiency, improve specificity
and sensitivity, reduce false positives and otherwise prove to be
more beneficial for patients and clinicians, the impact of supply
and manufacturing constraints or difficulties on our ability to
fulfill our orders, uncertainty of future sales levels, to defend
itself in litigation matters, protection of patents and other
proprietary rights, product market acceptance, possible
technological obsolescence of products, increased competition,
government regulation, changes in Medicare or other reimbursement
policies, risks relating to our existing and future debt
obligations, competitive factors, the effects of a decline in the
economy or markets served by the Company; and other risks detailed
in the Company’s filings with the Securities and Exchange
Commission. The words “believe,” “demonstrate,” “intend,” “expect,”
“estimate,” “will,” “continue,” “anticipate,” “likely,” “seek,” and
similar expressions identify forward-looking statements. Readers
are cautioned not to place undue reliance on those forward-looking
statements, which speak only as of the date the statement was made.
The Company is under no obligation to provide any updates to any
information contained in this release. For additional disclosure
regarding these and other risks faced by iCAD, please see the
disclosure contained in our public filings with the Securities and
Exchange Commission, available on the Investors section of our
website at http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.
Contact:
Media Inquiries:Jessica Burns, iCAD
+1-201-423-4492jburns@icadmed.com
Investor Inquiries:iCAD Investor Relationsir@icadmed.com
————————————————1 Niraula S, Biswanger N, Hu P, Lambert P,
Decker K. Incidence, Characteristics, and Outcomes of Interval
Breast Cancers Compared With Screening-Detected Breast Cancers.
JAMA Netw Open. 2020;3(9):e2018179.
doi:10.1001/jamanetworkopen.2020.181792 MQSA National Statistics.
Accessed via
https://www.fda.gov/radiation-emitting-products/mqsa-insights/mqsa-national-statistics.3
Graewingholt A, Rossi PG. (2021). Retrospective analysis of the
effect on interval cancer rate of adding an artificial intelligence
algorithm to the reading process for two-dimensional full-field
digital mammography. J Med Screen. 0(0) 1-3. Accessed via
https://journals.sagepub.com/doi/10.1177/09691413209880494
Eriksson, M et al. A risk model for digital breast tomosynthesis to
predict breast cancer and guide clinical care. Science
Translational Medicine. 14 (644). 2022 May 11. Accessed via
https://www.science.org/doi/10.1126/scitranslmed.abn3971.5 Eriksson
M, Czene K, Strand F et al. Identification of Women at High Risk of
Breast Cancer Who Need Supplemental Screening. Radiology. 2020 Sept
8.6 Eriksson M, CzeneK , Vachon C, Conant E, Hall P. Long-Term
Performance of an Image-Based Short-Term Risk Model for Breast
Cancer. Journal of Clinical Oncology. DOI:
10.1200/JCO.22.01564.
Icad (NASDAQ:ICAD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Icad (NASDAQ:ICAD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024